Evidence map›Paper›PMID 29750258›Full record

ArticleNucleic acids research2018

Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort.

Raphaël Leman, Pascaline Gaildrat, Gérald Le Gac, Chandran Ka, Yann Fichou, Marie-Pierre Audrezet, Virginie Caux-Moncoutier, Sandrine M Caputo, Nadia Boutry-Kryza, Mélanie Léone and 24 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 109 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Identification of a newMolecular genetics and metabolism reports · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 5 countries.

Raphaël LemanLaboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
Pascaline GaildratInserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
Gérald Le GacInserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
Chandran KaInserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
Yann FichouInserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
Marie-Pierre AudrezetInserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
Virginie Caux-MoncoutierInserm U830, Institut Curie Centre de Recherches, 75005 Paris, France.
Sandrine M CaputoService de Génétique, Institut Curie, 75005 Paris, France.
Nadia Boutry-KryzaUnité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, 69000 Lyon, France.
Mélanie LéoneUnité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, 69000 Lyon, France.
Sylvie MazoyerLyon Neuroscience Research Center-CRNL, Inserm U1028, CNRS UMR 5292, University of Lyon, 69008 Lyon, France.
Françoise Bonnet-DorionInserm U916, Département de Pathologie, Laboratoire de Génétique Constitutionnelle, Institut Bergonié, 33000 Bordeaux, France.
Nicolas SevenetInserm U916, Département de Pathologie, Laboratoire de Génétique Constitutionnelle, Institut Bergonié, 33000 Bordeaux, France.
Marine Guillaud-BatailleGustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
Etienne RouleauGustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
Brigitte Bressac-de PailleretsGustave Roussy, Université Paris-Saclay, Département de Biopathologie, 94805 Villejuif, France.
Barbara WappenschmidtDivision of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, University Hospital of Cologne, 50937 Cologne, Germany.
Maria RossingCentre for Genomic Medicine, Rigshospitalet, University of Copenhagen, 1017 Copenhagen, Denmark.
Danielle MullerLaboratoire d'Oncogénétique, Centre Paul Strauss, 67000 Strasbourg, France.
Violaine BourdonLaboratoire d'Oncogénétique Moléculaire, Institut Paoli-Calmettes, 13009 Marseille, France.
Françoise RevillonLaboratoire d'Oncogénétique Moléculaire Humaine, Centre Oscar Lambret, 59000 Lille, France.
Michael T ParsonsDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 4006 Herston, Queensland, Australia.
Antoine RousselinLaboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
Grégoire DavyLaboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
Gaia CastelainInserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
Laurent CastéraLaboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
Joanna SokolowskaService de Génétique, CHU Nancy, 54035 Nancy, France.
Florence CouletService de génétique, Hôpital Pitié Salpétrière, AP-HP, 75013 Paris, France.
Capucine DelnatteLaboratoire de génétique moléculaire, CHU Nantes, 44000 Nantes, France.
Claude FérecInserm UMR1078, Genetics, Functional Genomics and Biotechnology, Université de Bretagne Occidentale, 29200 Brest, France.
Amanda B SpurdleDepartment of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 4006 Herston, Queensland, Australia.
Alexandra MartinsInserm U1245 Genomics and Personalized Medecine in Cancer and Neurological Disorders, Normandie Univ, UNIROUEN, Normandy Centre for Genomic and Personalized Medicine, 76031 Rouen, France.
Sophie KriegerLaboratoire de Biologie Clinique et Oncologique, Centre François Baclesse, 14000 Caen, France.
Claude HoudayerInserm U830, Institut Curie Centre de Recherches, 75005 Paris, France.
Inserm · FRNormandie Université · FRCentre François Baclesse · FRGénétique, Génomique Fonctionnelle et Biotechnologies · FRHospices Civils de Lyon · FRInstitut Curie · FRInstitut Gustave Roussy · FRQIMR Berghofer Medical Research Institute · AUUniversité de Bretagne Occidentale · FRCentre Oscar Lambret · FRDélégation Paris 5 · FRInstitut Bergonié · FRInstitut Paoli-Calmettes · FRLaboratoire de Génétique Cellulaire · FRLevi Strauss (United States) · USRigshospitalet · DKSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Rouen Normandie · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variant interpretation is the key issue in molecular diagnosis. Spliceogenic variants exemplify this issue as each nucleotide variant can be deleterious via disruption or creation of splice site consensus sequences. Consequently, reliable in silico prediction of variant spliceogenicity would be a major improvement. Thanks to an international effort, a set of 395 variants studied at the mRNA level and occurring in 5' and 3' consensus regions (defined as the 11 and 14 bases surrounding the exon/intron junction, respectively) was collected for 11 different genes, including BRCA1, BRCA2, CFTR and RHD, and used to train and validate a new prediction protocol named Splicing Prediction in Consensus Elements (SPiCE). SPiCE combines in silico predictions from SpliceSiteFinder-like and MaxEntScan and uses logistic regression to define optimal decision thresholds. It revealed an unprecedented sensitivity and specificity of 99.5 and 95.2%, respectively, and the impact on splicing was correctly predicted for 98.8% of variants. We therefore propose SPiCE as the new tool for predicting variant spliceogenicity. It could be easily implemented in any diagnostic laboratory as a routine decision making tool to help geneticists to face the deluge of variants in the next-generation sequencing era. SPiCE is accessible at (https://sourceforge.net/projects/spicev2-1/).

Indexed as

Computer SimulationGenetic VariationRNA SplicingBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsComputational BiologyFemaleHumansInternational CooperationInternetOvarian NeoplasmsReproducibility of ResultsRNA Splice SitesSensitivity and SpecificityBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanRNA Splice Sites

Identifiers

PMID29750258
PMCPMC6125621
OpenAlexW2799503158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.